DEFA14A 1 d72093ddefa14a.htm DEFA14A DEFA14A

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 14A

Proxy Statement Pursuant to Section 14(a) of the

Securities Exchange Act of 1934

(Amendment No.     )

 

 

Filed by the Registrant  ☒                             Filed by a party other than the Registrant  ☐

Check the appropriate box:

 

  Preliminary Proxy Statement
  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
  Definitive Proxy Statement
  Definitive Additional Materials
  Soliciting Material Under §240.14a-12

Karyopharm Therapeutics Inc.

(Name of Registrant as Specified In Its Charter)

 

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

Payment of Filing Fee (Check the appropriate box):

  No fee required.
  Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.
  (1)  

Title of each class of securities to which transaction applies:

 

     

  (2)  

Aggregate number of securities to which transaction applies:

 

     

  (3)  

Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

 

     

  (4)  

Proposed maximum aggregate value of transaction:

 

     

  (5)  

Total fee paid:

 

     

  Fee paid previously with preliminary materials.
  Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.
  (1)  

Amount previously paid:

 

     

  (2)  

Form, Schedule or Registration Statement No.:

 

     

  (3)  

Filing party:

 

     

  (4)  

Date Filed:

 

     

 

 

 


                Important Notice Regarding the Availability of Proxy Materials for the

                Stockholder Meeting to Be Held on May 21, 2021.

                              
                        
   

 

Your Vote Counts!

          
 

 

KARYOPHARM THERAPEUTICS INC. 

 

2021 Annual Meeting

May 21, 2021 9:00 a.m. Eastern Time

Virtual Meeting Site: www.virtualshareholdermeeting.com/KPTI2021  

             

                    LOGO

   
 

LOGO     

   

 

KARYOPHARM THERAPEUTICS INC.

C/O PROXY SERVICES

P.O. BOX 9142

FARMINGDALE, NY 11735

        
   

    

    

   
 
 
      
 
     

    D42446-P51424

                                       
            
           

 You invested in KARYOPHARM THERAPEUTICS INC. and it’s time to vote!

You have the right to vote on proposals being presented at the Annual Meeting.

 Get informed before you vote

View the Notice and Proxy Statement and Annual Report on Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 9, 2021. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.proxyvote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy.

 

 

 

LOGO

 

  *

Please check the meeting materials for any special requirements for meeting attendance.

V1


Vote at www.proxyvote.com

 

 

THIS IS NOT A VOTABLE BALLOT

This is an overview of the more complete proxy materials that

are available to you on the Internet. We encourage you to access

and review all of the important information contained in the proxy

materials before voting. Please follow the instructions on the

reverse side to vote these important matters.

 

  Voting Items  

Board

Recommends

 

1.

  To elect the following three Class II director nominees:    
 
   

  1)  Deepika R. Pakianathan, Ph.D.

  2)  Richard Paulson, M.B.A.

  3)  Chen Schor, M.B.A., C.P.A.

 

    

  LOGO    

    

 

For

 

 

2.

  To approve, on an advisory basis, the compensation of Karyopharm’s named executive officers.     LOGO   For
 

3.

  To ratify the appointment of Ernst & Young LLP as Karyopharm’s independent registered public accounting firm for the year ending December 31, 2021.     LOGO   For

In their discretion, the proxies are authorized to vote upon such other matters as may be properly brought before the meeting or any adjournments or postponements thereof.

       

    

    

    

    

    

    

    

    

    

    

    

    

   

 

Prefer to receive an email instead? While voting on www.proxyvote.com, be sure to click “Sign up for E-delivery”.

D42447-P51424